Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RAPT Therapeutics (RAPT) EBIT: 2018-2023

Historic EBIT for Therapeutics (RAPT) over the last 6 years, with Dec 2023 value amounting to -$127.1 million.

  • Therapeutics' EBIT fell 35.96% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 48.10%. This contributed to the annual value of -$127.1 million for FY2023, which is 48.10% down from last year.
  • Per Therapeutics' latest filing, its EBIT stood at -$127.1 million for FY2023, which was down 48.10% from -$85.8 million recorded in FY2022.
  • In the past 5 years, Therapeutics' EBIT ranged from a high of -$43.6 million in FY2019 and a low of -$127.1 million during FY2023.
  • Its 3-year average for EBIT is -$94.0 million, with a median of -$85.8 million in 2022.
  • Data for Therapeutics' EBIT shows a maximum YoY crashed of 48.10% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Therapeutics' EBIT stood at -$43.6 million in 2019, then decreased by 21.97% to -$53.2 million in 2020, then tumbled by 30.06% to -$69.2 million in 2021, then dropped by 23.97% to -$85.8 million in 2022, then slumped by 48.10% to -$127.1 million in 2023.